PULSE and 35+ Other Stakeholders Urge Congress to Overturn FTC’s New HSR Rule

by Keishi Foecke | Feb 13, 2025 | Blog Post

This week, PULSE joined over 35 leading business and industry stakeholders in calling for leaders of the House Judiciary Committee to overturn the Biden Administration’s Hart-Scott-Rodino (HSR) premerger notification rule changes. In their letter to the Committee, the...

Pro-Innovation M&A Fuels Growth, Innovation in America’s Life Sciences Industry

by Keishi Foecke | Feb 6, 2025 | Blog Post

It’s critical that competition policies reflect the unique and fundamental role of mergers and acquisitions (M&A) in America’s life sciences industry. Policies that support pro-competitive life sciences M&A can help drive growth, incentivize investment and,...

NJBIZ Op-Ed: “Federal Anti-M&A Policy Could Undermine New Jersey’s Leadership in the Life Sciences”

by Keishi Foecke | Feb 4, 2025 | Blog Post, PULSE Partner

In a recent op-ed for NJBIZ, Debbie Hart, President and CEO of PULSE Partner BioNJ, discusses how federal policy against mergers and acquisitions (M&A) could undermine New Jersey’s leadership in the life sciences. Read the op-ed below:  As the “medicine chest of...

Innovations Advanced by M&A: A First-in-Class Therapy for Chronic Graft-Versus-Host Disease

by Keishi Foecke | Jan 29, 2025 | Blog Post, Innovations Advanced by M&A

This blog is another installment in a series, Innovations Advanced by M&A, that underscores the unique role of mergers and acquisitions in promoting a competitive and innovative life sciences ecosystem for patients. You can find previous blogs in this...

What They Are Saying: M&A Fuels Investment and Innovation in the American Life Sciences Industry

by Keishi Foecke | Jan 22, 2025 | Blog Post

In the wake of the 43rd J.P. Morgan Healthcare Conference held last week, industry leaders underscored the essential role of mergers and acquisitions (M&A) in fueling America’s life sciences industry. In this annual spotlight on the life sciences industry, M&A...